AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 04 2025
0mins
Source: Newsfilter
AccuStem Sciences Launches Blood Test: AccuStem Sciences plans to introduce its microRNA Signature Classifier (MSC) blood test for lung cancer screening, targeting over 1.6 million patients diagnosed with nodules annually in the US, with potential expansion to 15 million at-risk individuals.
Improvement in Lung Cancer Detection: The MSC test, developed to reduce false positives from low-dose computed tomography (LDCT), has shown significant accuracy in identifying lung cancer risk, potentially transforming standard care practices and reducing unnecessary procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
